Quantitative proteomic analysis of down syndrome biomarkers in maternal serum using isobaric tags for relative and absolute quantification (iTRAQ)

References

• Antonarakis SE. Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet. 2017;18:147–163.
   PubMed Web of Science ®Google Scholar
• Presson AP, Partyka G, Jensen KM, et al. Current estimate of Down Syndrome population prevalence in the United States. J Pediatr. 2013;163:1163–1168.
   PubMed Web of Science ®Google Scholar
• Cho CK, Smith CR, Diamandis EP. Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. J Proteome Res. 2010;9:3574–3582.
   PubMed Web of Science ®Google Scholar
• Kwon JY, Park IY, Kwon SM, et al. The quadruple test for Down syndrome screening in pregnant women of advanced maternal age. Arch Gynecol Obstet. 2012;285:629–633.
   PubMed Web of Science ®Google Scholar
• Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005;353:2001–2011.
   PubMed Web of Science ®Google Scholar
• Miao ZY, Liu X, Shi TK, et al. First trimester, second trimester, and integrated screening for Down’s syndrome in China. J Med Screen. 2012;19:68–71.
   PubMed Web of Science ®Google Scholar
• Reddy UM, Mennuti MT. Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop. Obstet Gynecol. 2006;107:167–173.
   PubMed Web of Science ®Google Scholar
• Nagalla SR, Canick JA, Jacob T, et al. Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. J Proteome Res. 2007;6:1245–1257.
   PubMed Web of Science ®Google Scholar
• Kolla V, Jenö P, Moes S, et al. Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J Biomed Biotechnol. 2010;952047:5.
   Google Scholar
• Sui W, Zhang R, Chen J, et al. Quantitative proteomic analysis of Down syndrome in the umbilical cord blood using iTRAQ. Mol Med Rep. 2015;11:1391–1399.
   PubMed Web of Science ®Google Scholar
• Wang K, Wang X, Zheng S, et al. iTRAQ-based quantitative analysis of age-specific variations in salivary proteome of caries-susceptible individuals. J Transl Med. 2018;16:293.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang R, Wei J, et al. Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic Analysis. Biomed Res Int. 2018;2018:5484976.
   PubMedGoogle Scholar
• Wisniewski JR, Zougman A, Nagaraj N, et al. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–362.
   PubMed Web of Science ®Google Scholar
• Dimitriadou F, Phocas I, Mantzavinos T, et al. Discordant secretion of pregnancy specific β1-glycoprotein and human chorionic gonadotropin by human pre-embryos cultured in vitro. Fertil Steril. 1992;57:631–636.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Bapna BC, Mapa MK, et al. Pregnancy specific proteins: suppression of in vitro blastogenic response to mitogen by these proteins. Int J Fertil. 1982;27:66–69.
   PubMedGoogle Scholar
• Harris SJ, Anthony FW, Jones DB, et al. Pregnancy-specific-β1-glycoprotein: effect on lymphocyte proliferation in vitro. J Reprod Immunol. 1984;6:267–270.
   PubMed Web of Science ®Google Scholar
• Cheng YH, Imir A, Suzuki T, et al. SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006;75:605–614.
   PubMed Web of Science ®Google Scholar
• Rajtar-Ciosek A, Wyroba J, Kacalska-Jansen O, et al. Markers of implantation in ectopic and high-risk early eutopic pregnancies. Folia Med Cracov. 2016;56:41–50.
   PubMedGoogle Scholar
• Redecker B, Heckendorf B, Grosch HW, et al. Molecular organization of the human cathepsin D gene. DNA Cell Biol. 1991;10:423–431.
   PubMed Web of Science ®Google Scholar
• Lenarčič B, Kos J, Dolenc I, et al. Cathepsin D inactivates cysteine proteinase inhibitors cystatins. Biochem Biophys Res Commun. 1988;154:765–772.
   PubMed Web of Science ®Google Scholar
• Levičar N, Strojnik T, Kos J, et al. Lysosomal enzymes, cathepsins in brain tumour invasion. Journal of Neuro-Oncology. 2002;58:21–32.
   PubMed Web of Science ®Google Scholar
• Sheikh MS, Augereau P, Chalbos D, et al. Retinoid regulation of human cathepsin D gene expression. J Steroid Biochem Mol Biol. 1996;57:283–291.
   PubMed Web of Science ®Google Scholar
• Ginsberg SD, Hemby SE, Lee VMY, et al. Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons. Ann Neurol. 2000;48:77–87.
   PubMed Web of Science ®Google Scholar
• Schwagerl AL, Mohan PS, Cataldo AM, et al. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem. 2002;64:443–446.
   Google Scholar
• Liaudetcoopman E, Beaujouin M, Derocq D, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 2006;237:167–179.
   PubMed Web of Science ®Google Scholar
• Leto G, Gebbia N, Rausa L, et al. Cathepsin D in the malignant progression of neoplastic diseases. Anticancer Res. 1992;12:235–240.
   PubMed Web of Science ®Google Scholar
• Foekens JA, Look MP, Bolt-de Vries J, et al. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer. 1999;79:300.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Coccia R, Cocciolo A, et al. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer’s disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta. 2013;1832:1249–1259.
   PubMed Web of Science ®Google Scholar
• Sun L, Ye RD. Serum amyloid A1: structure, function and gene polymorphism. Gene. 2016;583:48–57.
   PubMed Web of Science ®Google Scholar
• Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37:381–388.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454.
   PubMed Web of Science ®Google Scholar
• Kumon Y, Sipe JD, Brinckerhoff CE, et al. Regulation of extrahepatic apolipoprotein serum amyloid A (ApoSAA) gene expression by interleukin-1 alpha alone: synthesis and secretion of ApoSAA by cultured aortic smooth muscle cells. Scand J Immunol. 1997;46:284–291.
   PubMed Web of Science ®Google Scholar
• Rajkovic I, Denes A, Allan SM, et al. Emerging roles of the acute phase protein pentraxin-3 during central nervous system disorders. J Neuroimmunol. 2016;292:27–33.
   PubMed Web of Science ®Google Scholar
• Liang JS, Sloane JA, Wells JM, et al. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci Lett. 1997;225:73–76.
   PubMed Web of Science ®Google Scholar
• Miida T, Yamada T, Seino U, et al. Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim Biophys Acta. 2006;1761:424–433.
   PubMed Web of Science ®Google Scholar
• Baranova IN, Vishnyakova TG, Bocharov AV, et al. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem. 2005;280:8031–8040.
   PubMed Web of Science ®Google Scholar
• Lee HY, Kim SD, Baek SH, et al. Serum amyloid A stimulates macrophage foam cell formation via lectin-like oxidized low-density lipoprotein receptor 1 upregulation. Biochem Biophys Res Commun. 2013;433:18–23.
   PubMed Web of Science ®Google Scholar